Pancreas cancer: Therapeutic trials in metastatic disease

Volume: 123, Issue: 6, Pages: 1475 - 1488
Published: Apr 8, 2021
Abstract
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism,...
Paper Details
Title
Pancreas cancer: Therapeutic trials in metastatic disease
Published Date
Apr 8, 2021
Volume
123
Issue
6
Pages
1475 - 1488
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.